NLRP3 and bone neoplasm: Behavioral tests confirmed that both single and repetitive treatment with NLRP3 inhibitor MCC950 markedly attenuated cancer pain behaviors (Chen et al., 2019), suggesting that the activation of NLRP3/ASC/Caspase-1 signaling cascades is an essential step for the initiation and maintenance of central pain sensitization following bone cancer (Table 1).